Hanall Biopharma Launches 'Absito Tablets' for Gastroesophageal Reflux Disease Treatment

Hanall Biopharma Abscito Tablets.

[Asia Economy Reporter Lee Gwanju] HanAll BioPharma announced on the 4th that it has launched the gastroesophageal reflux disease treatment 'Apsito Tablets' (active ingredient: Fexuprazan Hydrochloride). With the addition of Apsito Tablets, HanAll BioPharma has expanded its existing gastrointestinal treatment portfolio, which includes 'Normix' and 'Biotop'.

Apsito Tablets 40mg is a new drug for gastroesophageal reflux disease in the potassium-competitive acid blocker (P-CAB) class, which was approved in January for the treatment of erosive gastroesophageal reflux disease. P-CAB class treatments are gaining attention as the next-generation drugs following proton pump inhibitors (PPIs), which have been widely used to treat gastroesophageal reflux disease.

Unlike existing PPI treatments, Apsito Tablets rapidly suppress gastric acid secretion without a separate activation process. Clinical trials have demonstrated its excellent efficacy in improving nighttime heartburn symptoms, and it can be taken regardless of meals, significantly enhancing patient convenience. It also has advantages such as low drug interactions and consistent efficacy.

With the launch of Apsito Tablets, HanAll BioPharma plans to strengthen its product competitiveness in the gastrointestinal treatment prescription market. The goal is to develop Apsito Tablets into a 10 billion KRW product within five years, following the existing bestsellers Normix and Biotop in the lower gastrointestinal treatment line.

Son Beomgyu, Director of Sales Support at HanAll BioPharma, said, "Apsito Tablets can help improve patients' quality of life by enhancing the rapid onset and duration of drug efficacy compared to existing treatments," adding, "We will expand the foundation of our representative portfolios, including gastrointestinal, endocrine, circulatory, and urinary systems, to strengthen our position in the domestic market."